UMPS anticorps (C-Term)
Aperçu rapide pour UMPS anticorps (C-Term) (ABIN631243)
Antigène
Voir toutes UMPS AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term
-
Specificité
- UMPS antibody was raised against the C terminal of UMPS
-
Purification
- Affinity purified
-
Immunogène
- UMPS antibody was raised using the C terminal of UMPS corresponding to a region with amino acids VGFISGSRVSMKPEFLHLTPGVQLEAGGDNLGQQYNSPQEVIGKRGSDII
-
-
-
-
Indications d'application
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
UMPS Blocking Peptide, (ABIN5616907), is also available for use as a blocking control in assays to test for specificity of this UMPS antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of UMPS antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- UMPS (Uridine Monophosphate Synthetase (UMPS))
-
Autre désignation
- UMPS
-
Sujet
- OPRT (UMPS) is involved in early events of pancreatic and gallbladder carcinogenesis and invasion of hepatocellular carcinomas. Orotate phosphoribosyltransferase is involved in the invasion and metastasis of colorectal carcinoma. Determination of OPRT levels in gastric carcinoma tissue enables to predict the response to S-1-based neoadjuvant/adjuvant chemotherapy.
-
Poids moléculaire
- 52 kDa (MW of target protein)
-
Pathways
- Ribonucleoside Biosynthetic Process
Antigène
-